
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Long-Term Debt
OSE Immunotherapeutics SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Long-Term Debt
€38.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
29%
|
CAGR 10-Years
46%
|
|
![]() |
Valneva SE
PAR:VLA
|
Long-Term Debt
€193m
|
CAGR 3-Years
23%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€59.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
28%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Long-Term Debt
€48.5m
|
CAGR 3-Years
77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
DBV Technologies SA
PAR:DBV
|
Long-Term Debt
$6.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Long-Term Debt
€78.7m
|
CAGR 3-Years
84%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Long-Term Debt?
Long-Term Debt
38.3m
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Long-Term Debt amounts to 38.3m EUR.
What is OSE Immunotherapeutics SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
46%
Over the last year, the Long-Term Debt growth was -1%. The average annual Long-Term Debt growth rates for OSE Immunotherapeutics SA have been 3% over the past three years , 29% over the past five years , and 46% over the past ten years .